NCT05842941 - HEALEY ALS Platform Trial - Regimen G DNL343 | Biotech Hunter

Enrollment

249

Participants

Timeline

Start Date

May 24, 2023

Primary Completion Date

October 29, 2024

Study Completion Date

October 29, 2024

Conditions

Amyotrophic Lateral Sclerosis

Interventions

DRUG

DNL343

DNL343 is administered orally once daily per day for 24 weeks.

DRUG

Matching Placebo

Matching placebo is administered orally once daily per day for 24 weeks.

Trial Locations (1)

Healey Center for ALS at Massachusetts General Hospital, Boston